• Evorel^® 50 is an oestrogen-only HRT patch applied to the skin twice weekly
• Evorel^® 50 should not be applied on or near the breasts
• Start with one Evorel 50 patch
• Maximum dose: 100 micrograms of estradiol/24h two Evorel 50 patches

Intact uterus or Hysterectomised women + endometriosis:
Add progestogen approved for addition to oestrogen treatment E.g. oral norethisterone, 1 mg/day or medroxyprogesterone acetate, 2.5 mg/day for at least 12–14 days every month/28 day cycle. Cyclic or continuous sequential.

Hysterectomised Women: Not recommended to add progestogen

Indications

• Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women.
• Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.

Efficacy:

In clinical trials relief of menopausal symptoms was achieved during the first few weeks of treatment.

Prevention of Osteoporosis :

In a clinical trial of two years duration comparing Evorel 50 to placebo, the increase in lumbar spine bone mineral density (BMD) with Evorel 50 was 4.46 ± 4.04 % (mean±SD). The percentage of women who maintained or gained BMD in the lumbar spine with Evorel 50 was 84%

Evorel also had an effect on hip BMD. The increase in BMD in the femoral neck with Evorel 50 was 1.26 ± 2.86 %. The percentage of women maintaining or gaining BMD in the femoral neck was 65 %.

In the total hip, the increase in BMD was 2.17 ± 2.33 % with Evorel 50. The percentage of women maintaining or gaining BMD in the total hip was 93 %, respectively

1. Evorel 50 Summary of Product Characteristics available on medicines.ie